News
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...
Careers at Novartis in Slovenia At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...
Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...
An adverse event (or side effect) is any unwanted medical occurrence in a patient who has been given a medicinal product. This can be any unfavourable and unintended sign, symptom, or disease ...
If you are a final year student of undergraduate or postgraduate studies in economics, business, computer and information science, social sciences, logistics, organizational sciences, electrical ...
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on ...
We must fundamentally reimagine the way we work and create a culture that brings out the best in our people to fulfill our purpose of reimagining medicine to improve and extend people’s lives. We ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to ...
Note: Report Adverse events for Novartis Products only. Alternatively, if you are unable to report the side effect electronically you can email your local Novartis Drug Safety Responsible person to: ...
Inclusion criteria For Cohort 1, Patient who meets all the following criteria can be included in this study: 1. Age ≥ 18 years at the time of signing the ICF; 2. Patient with a documented diagnosis of ...
Treating advanced prostate cancer demands more than clinical progress—it demands a new era of care, fueled by relentless innovation, collaborative efforts, and an unwavering push toward personalized ...
ノバルティス ファーマ株式会社について ノバルティス ファーマ株式会社は、スイス・バーゼルに本拠を置く革新的医薬品のグローバル製薬企業ノバルティスの日本法人です。ノバルティスは、より充実した健やかな毎日のために、「医薬の未来を描く(Reimagining Medicine)」ことを追求してい ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results